Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors

Diagnostic Assessment Study, Single Site and Prospective, comparing18F-DOPA PET and Multiparametric RMI in Initial Exploration of Diffuse Glial Tumors

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03525080

Acronym

GLIROPA

Enrollment

Registered

2018-05-15

Start date

2018-06-12

Completion date

2019-09-11

Last updated

2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Brain Tumor, Brain Neoplasms

Brief summary

For patient having a brain tumor, RMI is the standard exam for tumor characterization and determines initial surgery. The aim of this study is to assess if PET could provide additional information that could have an impact on surgery (indication and planification)

Interventions

DIAGNOSTIC_TESTPET imagery

Every patients will have a PET imagery in addition to standard MRI

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Suspected glial resectable tumor * Free and informed consent * Affiliated to French social security

Exclusion criteria

* Suspected high grade glioma * Surgical emergency * Pregnant or breastfeeding woman * Patient deprived of their liberty or under guardianship * Patient not able to follow study medical monitoring for geographical, social or psychological reasons * Treated with carbidopa, catechol-O-methyl transferase inhibitor, haloperidol, reserpine within 2 weeks before PET imagery

Design outcomes

Primary

Measure	Time frame	Description
PET pictures and MRI sequences comparison	Imagings performed up to 29 days after inclusion (before brain surgery)	Comparison of PET pictures and MRI sequences will be done in order to assess concordance between both imagings

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026